Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review.
Ma Y, Shi X, Zhao K, Hu S, Shi Y, Jiang Y, Liu Y, Lu L, Chang Y, Zhou F, Dai Y, Wu Z, Li S, Qian Z, Xu X, Li C, Shen B, Zhou G, Chen C, Wang X, Feng J.
Ma Y, et al. Among authors: chen c.
Front Oncol. 2024 Mar 28;14:1328844. doi: 10.3389/fonc.2024.1328844. eCollection 2024.
Front Oncol. 2024.
PMID: 38606104
Free PMC article.